We are delighted to launch our new online learning module exploring adverse event management of Tyrosine kinase inhibitors (TKI) toxicity. We hope that this interactive resource will help lung cancer nurse specialists to feel more informed about TKI therapy and how it can impact patients. The module is exclusively available to LCNUK members.
What does the module cover?
Tyrosine kinases (enzymes) regulate cell functions such as growth, division and control. Tyrosine kinase inhibitors (TKI) are a class of targeted therapies that block the actions of these enzymes, which are responsible for sending growth and division signals in cells. By inhibiting these enzymes, TKIs stop cancer calls from growing and dividing, putting cancer into remission or increasing lifespan.
However, with any cancer treatment, this treatment option does create adverse side effects caused by treatment toxicity, which need identifying and managing. This online learning module will introduce you to TKI, therapeutic indications and what areas of the body can be associated with adverse effects when they are used. It will also cover epidermal growth factor receptor (EGFR) inhibitors and how adverse events due to TKI toxicity can be identified and managed.
Let's get started!
Members can login to their dashboard to start learning today. Join LCNUK for immediate access to all of our online learning modules and a host of other member benefits.
Once you have logged in, you can begin our pre-learning questionnaire to assess your current knowledge of this subject. It will help you to measure how your understanding improves once you have completed the module.